Galectin Therapeutics Inc (GALT) income statement
GALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$2.98+0.07 (+2.41%)
Close on Nov 18, 2026Market cap $300.53MP/E –Yield –
Galectin Therapeutics Inc income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- 26.5%
Financial strength
- Current ratio
- 0.10
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 8.8%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?